ASCERT subanalysis compares procedural costs over long term

11/12/2012 | TCTMD.com

At every point measured, bypass surgery was more expensive than percutaneous coronary intervention, even though CABG demonstrated cost-effectiveness over the longer term, according to a subanalysis of the ASCERT trial reported in the New England Journal of Medicine and discussed at the annual meeting of the American Heart Association. Session co-moderator Dr. Ralph Brindis said many concerns must be taken into account when treatment decisions are made: "As we [care for] the patient, we have to not only think about issues of quality, but accountability, transparency and cost."

View Full Article in:

TCTMD.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI